Journal of the American Veterinary Medical Association · 2026
Lorazepam reduces recurrence of urethral obstruction in male cats: a prospective, randomized, double-blinded, placebo-controlled study.
СтатьяRandomized Controlled Trial, VeterinaryНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Splittstoesser Alexa, Kerley Jessica, Lulich Jody, Randall Aaron, Tart Kelly
Аннотация
OBJECTIVE: To determine the efficacy of lorazepam in reducing the rate of recurrence in first-time feline urethral obstruction (UO) and frequency of lower urinary tract (LUT) signs following hospitalization, as well as adverse effects of the medication.
METHODS: This was a prospective, randomized, double-blinded, placebo-controlled study of 80 client-owned male cats presenting to a university teaching hospital with UO between 2021 and 2025. Cats with urolithiasis or urinary tract infection were excluded. Cats received lorazepam or placebo for 1 month after hospitalization for UO.
RESULTS: 41 cats received lorazepam and 39 cats received placebo. Seventy-two cats completed the study. Five of 72 cats experienced recurrence of UO, all receiving placebo. No cats receiving lorazepam had UO recurrence (0%; 95% CI, 0.0% to 10.9%) compared to the placebo group (15.7%; 95% CI, 5.2% to 33.7%); this was statistically significant. There was a statistically significant reduction in LUT signs for 2 of 33 cats during days 8 to 15 (95% CI, 0.7% to 20.2%) and 1 of 31 cats during days 16 to 30 (95% CI, 0.1% to 16.7%) for the lorazepam group. Ataxia was the only statistically significant side effect of lorazepam, occurring in 4 of 31 cats (13%); other reported effects included sedation, increased appetite, and vocalization.
CONCLUSIONS: Lorazepam administration was associated with a reduction in the recurrence of UO in this study population, as well as reduced LUT signs compared to cats receiving placebo. Lorazepam administration was found to be safe.
CLINICAL RELEVANCE: Lorazepam may be used safely in the reduction of both recurrent UO and LUT signs following alleviation of UO in male cats.
METHODS: This was a prospective, randomized, double-blinded, placebo-controlled study of 80 client-owned male cats presenting to a university teaching hospital with UO between 2021 and 2025. Cats with urolithiasis or urinary tract infection were excluded. Cats received lorazepam or placebo for 1 month after hospitalization for UO.
RESULTS: 41 cats received lorazepam and 39 cats received placebo. Seventy-two cats completed the study. Five of 72 cats experienced recurrence of UO, all receiving placebo. No cats receiving lorazepam had UO recurrence (0%; 95% CI, 0.0% to 10.9%) compared to the placebo group (15.7%; 95% CI, 5.2% to 33.7%); this was statistically significant. There was a statistically significant reduction in LUT signs for 2 of 33 cats during days 8 to 15 (95% CI, 0.7% to 20.2%) and 1 of 31 cats during days 16 to 30 (95% CI, 0.1% to 16.7%) for the lorazepam group. Ataxia was the only statistically significant side effect of lorazepam, occurring in 4 of 31 cats (13%); other reported effects included sedation, increased appetite, and vocalization.
CONCLUSIONS: Lorazepam administration was associated with a reduction in the recurrence of UO in this study population, as well as reduced LUT signs compared to cats receiving placebo. Lorazepam administration was found to be safe.
CLINICAL RELEVANCE: Lorazepam may be used safely in the reduction of both recurrent UO and LUT signs following alleviation of UO in male cats.